RxDoctor Payments Data

Wenchiang Han, MD

Neurology · Marysville, CANPI 1477545721

Payments from drug & device makers

$14,433in general payments, 2019–2025

Across 815 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Biogen$799
  • UCB, Inc.$669
  • Neurocrine Biosciences, Inc.$605
  • SK Life Science, Inc.$572
  • EMD Serono, Inc.$508
  • plus $8K from 39 others

What the payments were for

  • Speaking & faculty fees$360%
  • Food & beverage$14,30799%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,433 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$292,352
Medicare patients
833
Services billed
9,623

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa36$68,806
NuedextaDextromethorphan Hbr/Quinidine33$50,648
AmpyraDalfampridine12$50,203
XcopriCenobamate35$46,952
BotoxOnabotulinumtoxina15$33,505
Aimovig AutoinjectorErenumab-Aooe35$32,996
ElyxybCelecoxib19$31,808
AptiomEslicarbazepine Acetate17$30,954
Nurtec OdtRimegepant Sulfate25$30,424
Memantine Hcl173$11,452
Carbidopa-Levodopa ErCarbidopa/Levodopa106$8,886
Entacapone46$7,628
EliquisApixaban12$6,942
Mycophenolate Mofetil37$6,045
Levetiracetam158$5,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide$339$76,72698 claims
Avanir Pharmaceuticals, Inc.Nuedexta$173$50,64833 claims
Acorda Therapeutics, IncAmpyra$183$50,20312 claims
SK Life Science, Inc.Xcopri$572$46,95235 claims
PfizerNurtec Odt, Eliquis$383$37,36637 claims
AbbVieBotox$3,725$33,50515 claims
Scilex Pharmaceuticals Inc.Elyxyb$24$31,80819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in Marysville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →